Does sex affect worsening of cognitive and IADL functions in PD with and without PD-MCI?
Objective: To define how sex affects worsening of cognition and instrumental activities of daily living (IADLs) in a heterogeneous cohort of people with Parkinson’s disease…Impact of deep brain stimulation of the subthalamic nuclei on non-motor symptoms in Parkinson’s disease: a monocentric prospective study with a 12-month follow-up
Objective: The aim of the study is to evaluate the evolution of non-motor symptoms in Parkinson's disease (PD) in patients treated with deep brain stimulation…Multicenter, randomized, placebo-controlled, double-blind, parallel-group proof-of-concept study of lixisenatide in patients with early Parkinson’s disease (PD): the LIXIPARK trial (NCT03439943)
Objective: To evaluate the “disease-modifying” effect of lixisenatide as adjunct to antiparkinsonian medications in patients with early PD. Background: Lixisenatide, a glucagon-like peptide 1 receptor…The feasibility and efficacy of speech therapy via video call in patients with Parkinson’s disease: a preliminary study
Objective: To evaluate the feasibility and efficacy of video call-based speech therapy for patients with Parkinson’s disease (PD) with speech problems. Background: PD patients commonly…The natural history of Parkinson’s disease in LRRK2 G2019S carriers
Objective: To document differences between the evolution of self-reported symptoms and prodromal markers in LRRK2 G2019S carriers and non-carriers with and without Parkinson’s Disease (PD).…Management of Sigmoid Volvulus in Parkinson’s patients presenting to Royal Berkshire Hospital, Reading ,UK.
Objective: To evaluate acute management of volvulus in Parkinson’s Background: Constipation affects upto 50% of patients with Parkinson's and sigmoid volvulus is an under recognized…Demographic, clinical and genetic factors affecting amantadine response among patients with Parkinson disease
Objective: To identify factors that correlate with efficacy and tolerability of amantadine to predict therapeutic outcomes Background: Amantadine is the only commercially available medication to…Substantia Nigra blood-brain barrier opening in Parkinson´s disease: PET (18F-Choline) evidence of parenchymal penetration
Objective: To evaluate clinical safety, feasibility, and tissue penetration (by 18F-Choline PET) of MR-guided focused ultrasound (MRgFUS) blood-brain barrier opening (BBB-O) of the substantia nigra…Identification of pre-frailty in the elderly through serum metabolomics and its impact on Parkinson’s disease phenotype
Objective: We attempted to better characterize pre-frailty using serum metabolomics in a large cohort of elderly subjects without neurodegenerative diseases. Next, we sought to investigate…Relationship between sleep quality, fear of fall and falls history in people with Parkinson’s disease
Objective: We aimed to investigate the relationship of sleep quality with falls and fear of fall (FOF) in people with Parkinson's disease (PwPD). Background: Fall…
- « Previous Page
- 1
- …
- 222
- 223
- 224
- 225
- 226
- …
- 436
- Next Page »